Skip to main content
Caplight Logo









Cyrus Therapeutics

Cyrus Therapeutics

Private
SeoulHealthcare & Life Scienceshttp://cyrustx.com/kr/index.php

Last Round

Series C

Nov 11, 2025

Total Funding Raised

$47.74M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cyrus Therapeutics is a biotechnology company that develops small molecule medicines and next-generation anticancer drugs targeting undruggable proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

targeted protein degradersTPDdegrader-antibody conjugatesDACsmall molecule therapeuticsoncologyundruggable proteinsmolecular adhesive degradersMGDdrug discoverybiotechprecision medicinenext-generation sequencingNGSai drug discoverypharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cyrus Therapeutics Comparables

Compare Cyrus Therapeutics with similar companies based on industry and business-model similarity.

Cyrus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pin Therapeutics
89%
Ubix Therapeutics
87%
Illimis Therapeutics
85%

Cyrus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 11, 2025
Series BJan 27, 2022
Series ASep 28, 2020

Cyrus Therapeutics Investors

Notable investors and investment history

Cyrus Therapeutics investors
InvestorRounds
Paratus InvestmentSeries A, Series B
Timefolio Asset ManagementSeries A, Series B
Mirae Asset CapitalSeries B
Kolon InvestmentSeries A, Series B
Mirae Asset Venture InvestmentSeries B
Atinum InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 39% MoM, reaching 3.9K.

  • May 12, 2026

    Monthly visitors increased 44% MoM.

Cyrus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cyrus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cyrus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range16
Year Founded2019
Last FundingNov 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?